Possible serious side effects of deuterated colexitinib tablets

Deucravacitinib has shown good tolerability and a relatively low incidence of adverse reactions in clinical trials of plaque psoriasis. However, as a targeted drug that acts on the immune system, it may still cause some serious side effects, especially in certain groups of people, which requires close monitoring. According to the FDA-approved instructions and overseas phase III clinical data, serious side effects that need to be focused on include infection risk, liver function damage, immune abnormalities and laboratory index changes.

First of all, although deuterated colexitinib is highly selective and should not broadly suppress the immune system in theory, it may still increase the incidence of upper respiratory tract infections, especially mild to moderate infections such as nasopharyngitis and bronchitis, which are the most common. Some case reports show that patients may develop more serious bacterial or viral infections during treatment. Therefore, it is recommended to check for potential infections such as tuberculosis and hepatitis B before treatment, and to regularly monitor infection symptoms during medication.

Secondly, abnormal liver function is a risk that needs to be monitored closely. Some patients may experience elevated transaminases during medication, indicating damage to liver cells. Especially in patients taking concomitant medications or with a history of liver disease, it is necessary to regularly draw blood to check liver enzyme levels and avoid using it in combination with other hepatotoxic drugs. It is worth noting that the instructions clearly state that deuterated colexitinib is contraindicated in patients with severe liver damage, suggesting that it is highly dependent on liver function.

In addition, some patients have experienced laboratory abnormalities such as increased creatinine, blood lipid changes, and leukopenia during long-term medication. Although most of them are reversible and mild changes, blood routine, renal function and other indicators still need to be monitored regularly. For pregnant and lactating women, the current research data is insufficient and the use of this drug is not recommended.

In general, although deuterated coxitinib is considered to be safer than traditionalJAK inhibitors, as an immunomodulatory drug, it still needs to be used rationally under the guidance of a doctor. Patients should undergo a comprehensive assessment before treatment to rule out serious underlying diseases. Maintaining regular follow-up visits and laboratory monitoring during treatment is the key to ensuring efficacy and avoiding serious adverse reactions.

Reference materials:https://go.drugbank.com/drugs/DB16650